摘要
IL-6/STAT3通路是非小细胞肺癌发展的关键途径之一,可通过参与癌细胞的抗凋亡、增殖及肿瘤血管生成等多种恶性表型促进肿瘤发展。此外,临床研究表明,IL-6/STAT3信号通路与非小细胞肺癌的化疗、靶向及放疗耐药相关,针对IL-6/STAT3信号通路的靶向药物对非小细胞肺癌的治疗有益,有望成为治疗非小细胞肺癌的有效药物。深入了解IL-6/STAT3信号通路与非小细胞肺癌的关系有助于阐明非小细胞肺癌发病机制,并为其治疗提供新方向。本文就该通路在非小细胞肺癌发展及治疗中的最新进展作一综述。
The IL‐6/STAT3 pathway is one of the key pathways in the development of non-small cell lung can-cer (NSCLC), which can promote the development of tumor by participating in various malignant phenotypes such as anti-apoptosis, proliferation and tumor angiogenesis. In addition, clinical stud-ies have shown that IL‐6/STAT3 signaling pathway is associated with chemotherapy, targeting and radiotherapy resistance of NSCLC. Targeted drugs targeting IL‐6/STAT3 signaling pathway are ben-eficial for the treatment of NSCLC and are expected to be effective drugs for the treatment of NSCLC. A deeper understanding of the relationship between IL-6/STAT3 signaling pathway and NSCLC will help clarify the pathogenesis of NSCLC and provide a new direction for its treatment. This article re-views the latest progress of this pathway in the development and treatment of non-small cell lung cancer.
出处
《临床医学进展》
2022年第11期9953-9960,共8页
Advances in Clinical Medicine
